Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCRNASDAQ:SDGRNASDAQ:TRMLNASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$28.55-3.4%$28.75$23.15▼$58.36$1.43B0.75427,449 shs541,139 shsSDGRSchrödinger$23.76-1.7%$22.73$16.60▼$28.47$1.77B1.84838,934 shs713,906 shsTRMLTourmaline Bio$15.54-1.5%$15.57$11.56▼$29.79$399.15M2.11269,612 shs264,132 shsWVEWave Life Sciences$6.39-3.2%$7.70$4.25▼$16.74$984.64M-0.921.27 million shs1.23 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore-3.35%+1.75%+7.37%-3.42%-49.90%SDGRSchrödinger-1.70%+0.85%-2.98%-0.42%+2.50%TRMLTourmaline Bio-1.52%+6.88%+18.63%+17.46%+7.62%WVEWave Life Sciences-3.18%-0.31%+13.10%-41.43%+12.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMCRImmunocore2.9724 of 5 stars4.30.00.00.03.54.20.0SDGRSchrödinger2.2153 of 5 stars3.51.00.00.02.52.50.6TRMLTourmaline Bio2.6141 of 5 stars3.53.00.00.03.12.50.0WVEWave Life Sciences4.3163 of 5 stars3.51.00.04.82.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCRImmunocore 2.50Moderate Buy$58.13103.59% UpsideSDGRSchrödinger 3.00Buy$32.8038.05% UpsideTRMLTourmaline Bio 3.00Buy$49.33217.46% UpsideWVEWave Life Sciences 3.00Buy$21.17231.25% UpsideCurrent Analyst Ratings BreakdownLatest TRML, SDGR, IMCR, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/5/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.005/5/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/29/2025WVEWave Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/23/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.004/8/2025WVEWave Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$18.004/7/2025IMCRImmunocoreMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.003/26/2025WVEWave Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCRImmunocore$310.20M4.61N/AN/A$7.42 per share3.85SDGRSchrödinger$230.49M7.53$0.63 per share37.42$7.60 per share3.13TRMLTourmaline BioN/AN/AN/AN/A$10.08 per shareN/AWVEWave Life Sciences$108.30M9.09N/AN/A$0.40 per share15.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%N/ASDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)TRMLTourmaline Bio-$42.12M-$3.21N/AN/AN/AN/A-20.97%-20.56%N/AWVEWave Life Sciences-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%N/ALatest TRML, SDGR, IMCR, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025WVEWave Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/2/2025Q1 2025TRMLTourmaline Bio-$0.91-$0.89+$0.02-$0.89N/AN/A3/13/2025Q4 2024TRMLTourmaline Bio-$0.91-$0.86+$0.05-$0.86N/A$0.04 million3/4/2025Q4 2024WVEWave Life Sciences-$0.17$0.17+$0.34$0.17$25.60 million$83.75 million2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCRImmunocoreN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/AWVEWave Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCRImmunocore1.033.783.76SDGRSchrödingerN/A4.114.11TRMLTourmaline BioN/A40.3340.33WVEWave Life SciencesN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCRImmunocore84.50%SDGRSchrödinger79.05%TRMLTourmaline Bio91.89%WVEWave Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipIMCRImmunocore10.40%SDGRSchrödinger8.60%TRMLTourmaline Bio11.02%WVEWave Life Sciences29.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCRImmunocore32050.07 million45.48 millionOptionableSDGRSchrödinger79073.04 million66.59 millionOptionableTRMLTourmaline Bio4425.69 million22.82 millionOptionableWVEWave Life Sciences240154.09 million108.14 millionOptionableTRML, SDGR, IMCR, and WVE HeadlinesRecent News About These CompaniesB. Riley Has Pessimistic Outlook of WVE FY2029 EarningsMay 14 at 4:31 AM | marketbeat.comFY2028 Earnings Estimate for WVE Issued By WedbushMay 14 at 4:31 AM | marketbeat.comIs Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?May 13 at 7:10 PM | msn.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by The Manufacturers Life Insurance CompanyMay 13 at 4:16 AM | marketbeat.comAlgert Global LLC Invests $527,000 in Wave Life Sciences Ltd. (NASDAQ:WVE)May 13 at 3:58 AM | marketbeat.comStockNews.com Downgrades Wave Life Sciences (NASDAQ:WVE) to SellMay 12 at 1:22 AM | americanbankingnews.comDriehaus Capital Management LLC Raises Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 10, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Shares Gap Down Following Weak EarningsMay 10, 2025 | americanbankingnews.comWave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comWAVE Life Sciences Ltd (WVE) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 9, 2025 | finance.yahoo.comWAVE Life Sciences Ltd (WVE) Q1 2025 Earnings Call Highlights: Clinical Advancements and ...May 9, 2025 | finance.yahoo.comVoya Investment Management LLC Boosts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)May 9, 2025 | marketbeat.comWave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue EstimatesMay 8, 2025 | zacks.comWave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comBamco Inc. NY Invests $1.05 Million in Wave Life Sciences Ltd. (NASDAQ:WVE)May 8, 2025 | marketbeat.comWave Life Sciences Q1 2025 Earnings PreviewMay 7, 2025 | msn.comWave Life Sciences (NASDAQ:WVE) Sees Unusually-High Trading Volume - Still a Buy?May 7, 2025 | marketbeat.comRenaissance Technologies LLC Lowers Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)May 6, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Sold by 683 Capital Management LLCMay 4, 2025 | marketbeat.comResearch Analysts Offer Predictions for WVE FY2026 EarningsMay 3, 2025 | marketbeat.comCantor Fitzgerald Predicts WVE FY2025 EarningsMay 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRML, SDGR, IMCR, and WVE Company DescriptionsImmunocore NASDAQ:IMCR$28.55 -0.99 (-3.35%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$29.00 +0.45 (+1.57%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Schrödinger NASDAQ:SDGR$23.76 -0.41 (-1.70%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$23.72 -0.05 (-0.19%) As of 07:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Tourmaline Bio NASDAQ:TRML$15.54 -0.24 (-1.52%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$16.55 +1.01 (+6.51%) As of 07:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Wave Life Sciences NASDAQ:WVE$6.39 -0.21 (-3.18%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$6.37 -0.02 (-0.30%) As of 07:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
